Abcam, ab250350, Anti-TRAP220/MED1 (phospho T1457) antibody [EPR13269] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TRAP220/MED1 phospho T1457 antibody. Carrier free. Suitable for Dot, WB, IHC-P and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR13269,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Dot, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250350 is the carrier-free version of
ab181103
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRAP220 also known as MED1 is a protein with a molecular mass of approximately 220 kDa. It plays an important role as a component of the mediator complex which is important for transcription regulation. The expression of TRAP220/MED1 is found in various tissues with higher levels observed in liver lung and heart tissues. This protein acts mechanistically as a bridge between gene-specific transcription factors and RNA polymerase II facilitating the assembly of the pre-initiation complex.
Biological function summary
TRAP220/MED1 functions within the larger mediator complex a multi-protein coactivator essential for gene transcription by RNA polymerase II. It plays an important role in nuclear receptor signaling facilitating the transcriptional activation by various nuclear hormone receptors. MED1 interacts directly with these receptors through its various domains allowing the transcription of target genes responsive to hormonal signals.
Pathways
TRAP220/MED1 contributes significantly to transcriptional activation pathways involving nuclear receptors such as the PPAR (Peroxisome Proliferator-Activated Receptor) and thyroid hormone receptor pathways. It closely interacts with other proteins in these pathways including MED12 and MED14 which form integral parts of the mediator complex's function. Its involvement in these pathways highlights its critical role in lipid metabolism and energy homeostasis.
TRAP220/MED1 is associated with metabolic and proliferative diseases. Its altered expression or mutations can lead to conditions such as obesity and cancer. For instance aberrant MED1 activity or expression levels have connections to breast cancer development through its role in estrogen receptor-mediated gene expression. This correlation emphasizes the protein's potential impact in various pathophysiological contexts driving ongoing research into MED1 as a therapeutic target.